Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial
Background Although safety and tolerability of vericiguat were established in the VICTORIA (Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction) trial in patients with heart failure with reduced ejection fraction, some subgroups may be more susceptible to symptomati...
Guardado en:
Autores principales: | Carolyn S. P. Lam, Hillary Mulder, Yuri Lopatin, Jose B. Vazquez‐Tanus, David Siu, Justin Ezekowitz, Burkert Pieske, Christopher M. O’Connor, Lothar Roessig, Mahesh J. Patel, Kevin J. Anstrom, Adrian F. Hernandez, Paul W. Armstrong |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/746573cb9e5446779c083cce06f77a82 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Nonalcoholic Fatty Liver Disease and Risk of Heart Failure Among Medicare Beneficiaries
por: Marat Fudim, et al.
Publicado: (2021) -
Recent and Upcoming Drug Therapies for Pediatric Heart Failure
por: Karla L. Loss, et al.
Publicado: (2021) -
Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review
por: Domingo Pascual-Figal, et al.
Publicado: (2021) -
A study of association between heart failure with preserved ejection fraction with hypertension and diabetes mellitus
por: Swapan Sarkar, et al.
Publicado: (2021) -
Factors associated with prolonged hospitalization, readmission, and death in elderly heart failure patients in western Romania
por: Gyalai-Korpos I, et al.
Publicado: (2015)